Pharmacogenomics of arylamine N-acetyltransferases - From drug metabolism to drug discovery

Pharmacogenomics

Volumn 3, Issue 6, 2002, Pages 729-731

  Sim, Edith ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; ENZYME INHIBITOR; ISONIAZID; TUBERCULOSTATIC AGENT;

ALLELE; BACTERIUM ISOLATE; DRUG ACETYLATION; DRUG INACTIVATION; DRUG METABOLISM; DRUG RESEARCH; DRUG RESPONSE; DRUG TARGETING; EDITORIAL; ENZYME INDUCTION; ENZYME STRUCTURE; ENZYME SUBSTRATE; ETHNIC DIFFERENCE; GENE ACTIVITY; GENE DELETION; GENE DUPLICATION; GENE EXPRESSION REGULATION; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENETIC REGULATION; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; MEDICAL INFORMATION; MOLECULAR CLONING; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHARMACOGENOMICS; PROTEIN EXPRESSION; PSEUDOGENE; RAT; SINGLE NUCLEOTIDE POLYMORPHISM; TUBERCULOSIS;

ANIMALS; ARYLAMINE N-ACETYLTRANSFERASE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; TECHNOLOGY, PHARMACEUTICAL;

BACTERIA (MICROORGANISMS); MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS;

EID: 0036850234     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.3.6.729     Document Type: Editorial

References (10)

1. Boukouvala S, Price N, Sim E: Identification and functional characterization of novel polymorphisms associated with the genes for arylamien N-acetyltransferase in mice. Pharmacogenetics 12, 385-394 (2002).
2. Butcher NJ, Ilett K, Minchin RF: Substrate-dependent regulation of human arylamine N-acetyltransferase-1 in cultured cells. Mol. Pharmacol. 57, 468-471 (2000)
3. DeLeon JH, Vatsis KP, Weber WW: Charcaterization of naturally-occurring and recombinant human N-acetyltransferase variants encoded by NAT1. Mol. Pharmacol. 58, 288-299 (2000).
4. Delomenie C, Fouix S, Longuemaux S et al.: Identification and functional characterisation of arylamine N-acetyltransferase in eubacteria: evidence for highly selective acetylation of 5-aminosalicylate. J. Bacteriol. 183, 3417-3427 (2001).
5. Leff MA, Fretland AJ, Doll MA et al.: Novel human N-acetyltransferase 2 alleles that differ in mechanism for slow acetylator phenotype. J. Biol. Chem. 274, 34519-34522 (1999).
6. Pompeo F, Brooke E, Kawamura A et al.: The pharmacogenetics of NAT: structural aspects. Pharmacogenomics 3, 19-30 (2002).
7. Rodrigues-Lima F, Blomeke B, Sim E et al.: NA T-from bugs to brains. An overview of the 2nd international workshop on the arylamine N-acetyltransferases. Pharmacogenomics J. 2, 152-155 (2002).
8. Upton A, Johnson N, Sandy J et al.: Arylamine N-acetyltransferases- of mice, men and microorganisms. Trends Pharmacol. 22, 140-146 (2001).
9. Upton AM, Mushtaq A, Victor TC et al.: Arylamine N-acetyltransferase of Mycobacterium tuberculosis is a polymorphic enzyme and a site of isoniazid metabolism. Mol. Microbiol. 42, 309-317 (2001).
10. Weber WW, Hein DW: Arylamine N-acetyltransferases. Pharmacol. Rev. 37, 25-79 (1985).